Assembly Biosciences Inc — datos financieros trimestrales (NASDAQ:ASMB) | MetaTrader

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Flujo de caja de las actividades operativas -407 K-23.44 M-16.76 M-15.13 M14.24 M -41.09 M Flujo de caja de las actividades de inversión -6.7 M6.59 M16.99 M-158.27 M21.22 M -113.47 M Flujo de caja de las actividades financieras 17 M1.92 M357 K171.93 M456 K 174.67 M Flujo de caja libre -407 K-23.44 M-16.76 M-15.18 M14.21 M -41.16 M

Noticias

Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development (ASMB)

Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates

Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes - Assembly Biosciences (NASDAQ:ASMB), Gilead Sciences (NASDAQ:GILD)

Gilead ejerce opción para programas de tratamiento del herpes de Assembly Bio

Gilead exercises option for Assembly Bio’s herpes treatment programs

Jefferies eleva precio objetivo de Assembly Biosciences a $62 tras datos de HSV

Jefferies eleva el precio objetivo de Assembly Biosciences a 62 dólares tras datos de HSV

Jefferies raises Assembly Biosciences stock price target to $62 on HSV data